Peptide LexiconAll compounds

Cortexin: The Russian Brain-Peptide Drug — What It Is, What Its Trials Compared and What They Leave Open

Cortexin is a mixture of peptides extracted from animal brain cortex, used in Russia for stroke, chronic brain ischaemia and cognitive problems. PubMed holds about 70 records with Cortexin in the title, most in one Russian neurology journal. Its largest recent trial, 490 stroke patients, compared Cortexin with Cortexin — no group went without it.

Used as a medicine in RussiaNot approved in the US or EU by any record foundTrials mostly add-on or open

Caroline S · Published 2026-11-19

Length

Not a single molecule: a mixture of peptides from animal brain cortex, so no single sequence, formula or weight

Sequence

None — a multi-component peptide preparation; a 2018 review describes it as containing 'a variety of neuropeptides' (PMID 30499504)

Origin

Extracted from animal cerebral cortex; developed in Russia, where nearly all its clinical studies are published

Last reviewed

2026-11-19

What is it good for?

In Russian practice it is given by injection, usually 10 mg a day for 10 days in the trials, alongside standard treatment for ischaemic stroke, chronic reduced blood flow to the brain, and cognitive or attention problems in children and adults. Its trials report better scores than standard care alone, but the largest compares two ways of giving Cortexin and none of the recent ones has a placebo-only group.

Illustration: A clear glass ampoule on a white surface, with a deep green and copper background.
Illustration

What it is

Cortexin is a peptide preparation extracted from animal cerebral cortex, used as a medicine in Russia. It is not a single molecule: a 2018 review in the Korsakov neurology journal groups it with "peptide hydrolysates derived from animal brain" and traces its proposed effects — on oxidative stress, inflammation and the enzyme caspase-8 — to "a variety of neuropeptides" in the mixture (Gulyaeva, PMID 30499504). Because it is a mixture, it has no sequence, formula or molecular weight of its own.

Property Value Source
Type Mixture of peptides from animal brain cortex PMID 30499504
How it is given Intramuscular; an intravenous form was tested in 2025 PMIDs 42133422, 41524350
Typical trial course 10 mg a day for 10 days PMIDs 42133422, 41782536
Defined relative Cortagen, Ala-Glu-Asp-Pro, designed from its amino-acid analysis PMID 15159690

Its closest relative in kind is Cerebrolysin, a pig-brain peptide preparation with trials outside Russia. Short synthetic peptides from the same Russian tradition include Semax and Pinealon.

What its trials compared

PubMed has 70 records with "cortexin" in the title (2026-11-19), most in the Russian journal Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. The four largest randomised studies whose abstracts were read:

Trial People What Cortexin was compared with Reported result
Fedin et al. 2025 (PMID 41524350) 490, acute ischaemic stroke Cortexin by the other route — IV v IM, double-dummy placebo mRS 0–2 at day 90: 93.6% v 86.5%; NIHSS fell 3.93 v 3.72; MMSE p = 0.249
Fedin et al. 2018 (PMID 30335070) 189, chronic cerebral ischaemia 20 mg v 10 mg v basic treatment only "Dose-dependent effect" on neurological symptoms, asthenia, sleep
DIACORT 2026 (PMID 42133422) 110, type 2 diabetes complications Base treatment (glycine, B vitamins) alone MoCA ×1.2; HbA1c 7.3% v 7.8%; 5 adverse events, 3 v 2
Schastnyy 2026 (PMID 41782536) 98, depressive disorder Antidepressants alone Larger MADRS fall and more "significant" self-rated improvement (p = 0.001)

The point the summaries skip: the largest trial gave Cortexin to every patient. It was designed to show that the intravenous form is no worse than the intramuscular one — the placebo was only there to keep both groups blinded to the route. It shows the two forms behave alike; it cannot show either works better than no Cortexin. The diabetes and depression trials compare Cortexin added to standard care with standard care alone, and their abstracts describe no placebo injection, so patients and assessors may have known who received the extra drug.

Animal work is broader. In rats with blocked brain arteries or narrowed carotids, Cortexin at 1 or 3 mg/kg for 10 days reduced damaged tissue and improved behavioural tests, alongside Cerebrolysin and Actovegin, and a radiolabelled dose crossed the blood–brain barrier in mice (Kurkin et al. 2021, PLoS One, PMID 34260655). Two of that paper's authors list Pharm-Holding CJSC, St Petersburg, as their affiliation.

What is not established

  • An effect against placebo in a large, independent trial. None was found; no Cortexin study is registered on ClinicalTrials.gov (2026-11-19).
  • Which peptides in the mixture do the work, and whether the composition is the same from batch to batch — the abstracts read do not report a characterisation.
  • Results outside Russia. The clinical records read are all from Russian centres; the few international-journal papers are laboratory or animal studies.
  • Registration details. The entry did not open the Russian state drug register; the trial reports describe it as a medicinal product.

Where it stands

Cortexin is a brain-derived peptide mixture with a sizeable Russian clinical literature built mostly on add-on and open comparisons. Decisions about stroke, cognition or depression treatment belong to a doctor; this entry records what the compound is and what its studies measured.

Sources opened 2026-11-19: PubMed E-utilities (title search; abstracts of PMIDs 42133422, 41782536, 41524350, 30499504, 30335070, 34260655); ClinicalTrials.gov API v2; Drugs@FDA via openFDA.

What the research shows

Improves recovery after ischaemic stroke

Fedin et al. 2025 (PMID 41524350): 490 patients randomised to intravenous or intramuscular Cortexin (double-dummy); 93.6% v 86.5% reached modified Rankin 0–2 at day 90. No group without Cortexin

Improves cognition and mood in diabetes complications

DIACORT 2026 (PMID 42133422): 110 patients, Cortexin 10 mg × 10 added to glycine and B vitamins v the base treatment alone; no placebo described in the abstract

Helps depression as an add-on

Schastnyy 2026 (PMID 41782536): 98 patients, Cortexin 10 mg IM × 10 added to antidepressants v antidepressants alone; no placebo described

Protects brain tissue in ischaemia

Kurkin et al. 2021, PLoS One (PMID 34260655): rat stroke and carotid-stenosis models; labelled Cortexin crossed the blood–brain barrier in mice

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Russia

Used as a medicine (the Russian trial reports call it 'лекарственный препарат'); this entry did not open the Russian drug register, so the registration details are not stated.

United States and EU

No record found: Drugs@FDA has no Cortexin product and ClinicalTrials.gov lists no Cortexin study (2026-11-19).

Published record

PubMed: 70 records with 'cortexin' in the title (2026-11-19), a few of them about unrelated molecules that share the word (the CTXN3 gene, a renal 'r-cortexin').

Frequently asked questions

What is Cortexin?

A Russian medicine made of peptides extracted from the brain cortex of animals. It is a mixture rather than one molecule, and is given by injection into a muscle or vein.

What is Cortexin used for?

In the Russian trials, ischaemic stroke, chronic reduced blood flow to the brain, cognitive problems after COVID-19 or in diabetes, depression as an add-on, and attention or learning problems in children. Most trials add it to standard treatment.

Does Cortexin work?

Its trials report better scores than standard treatment alone. But the recent ones either have no placebo group or compare two forms of Cortexin with each other, so they cannot separate the drug's effect from extra attention and expectation. No trial outside Russia was found.

Is Cortexin the same as Cerebrolysin?

No, though they are similar in kind. Both are peptide preparations from animal brain. Cerebrolysin is made from pig brain protein and has trials outside Russia, including a Cochrane review; Cortexin is a Russian preparation from brain cortex. Rat studies have compared the two.

How is Cortexin related to Cortagen?

Cortagen is a synthetic four-amino-acid peptide that its developers say they designed from the amino-acid make-up of Cortexin. Cortexin is the mixture; Cortagen is one defined chain.

Is Cortexin approved in the US or Europe?

No record of that was found. Drugs@FDA lists no Cortexin product, and none of its trials is registered on ClinicalTrials.gov.